Xueba is also open

Chapter 596 Johnson is Scared!

Although Johnson & Johnson is powerful and an industry leader, its path is quite different from that of Pfizer.

What is Johnson & Johnson's philosophy?
Decentralization = Creativity = Productivity!
Johnson & Johnson made its fortune in sterile dressings, but the products that are truly world-renowned are not sterile dressings. It may just be a "Band-Aid" created by one of his employees who cut his fingers while cooking, or Johnson & Johnson diapers, etc...

Johnson & Johnson has always believed that a small and fully authorized unit can create new products and develop new markets, so try to maintain a small and independent company, be responsible for production, marketing, distribution and research and development, and maintain independence after the acquisition of the new company, and continue to change from Separate companies from existing organizations.

Today, Johnson & Johnson owns 150 companies, of which more than 20 are major companies, and the rest are newly acquired companies, or are branched out of these 20 companies.

Each company is independent and 1972 percent owned by Johnson & Johnson.Under the philosophy of decentralization and innovation, Johnson & Johnson has grown by 1982 times in the 10 years from 4 to 1982. In 33, the sales volume reached 9000 billion US dollars, the number of employees worldwide reached 20, and the annual return on shareholders' equity Nearly [-]%. In recent years, under the advantage of marketization, under the mobilization of the World Trade Organization, the advantages of this model have been fully tapped, and it has gone further and further.

However, Johnson & Johnson has cooperated with China for a long time. In 1985, Johnson & Johnson established the first joint venture in China - Xi'an Janssen Pharmaceutical Co., Ltd.Subsequently, Shanghai Johnson & Johnson Co., Ltd., Johnson & Johnson (China) Co., Ltd., Johnson & Johnson (China) Medical Equipment Co., Ltd. and Shanghai Johnson & Johnson Pharmaceutical Co., Ltd. were successively established.

With the continuous development of business, today, Johnson & Johnson has more than 6000 employees in China, with a wide range of production fields, including consumer goods and personal care products, pharmaceutical products, medical equipment and diagnostic products.

However, the core competitiveness of Johnson & Johnson is not within these branches. These companies are just a commodity economy similar to the nature of enterprises.

Johnson & Johnson has begun to change in recent years, and began to emphasize the core, because the expansion of external products is only a value-added business, not a core competitiveness.

Just like the development of Xiaomi Group, within a period of time, it can rely on product diversification to continuously expand the market. However, without a core competitiveness, Xiaomi's future is limited.

On this point, Bai Ye had already had further communication with Boss Lei, and the other party had already started preparations.

As a large international enterprise, how could Johnson & Johnson fail to understand this?

Therefore, Bai Ye approached the Johnson & Johnson Group this time because he hoped to have core exchanges with Johnson & Johnson and strengthen each other.

In fact, compared to Pfizer, Bai Ye values ​​some aspects of Johnson & Johnson more, that is, the field of cooperation with Johnson & Johnson Group. This guy is really too big, like a behemoth, and its subsidiaries basically involve health-related peripheral industries. .

Therefore, cooperation with Johnson & Johnson can not only drive the development of medicine, but even drive the development of the entire economy.

China's manufacturing industry is still well-known in the world. For example, the decade-long lawsuit between Johnson & Johnson and China's Guilin Zhonghui Company over blood sugar test strips can be seen. The people of the Chinese nation have never lacked creativity and productivity.

Moreover, the development model of Bai Ye's current check and balance group is very similar to the current Johnson & Johnson Group!
It's just that the marketing model is different.

The coverage rate of Check & Balance Group's products is very high, and it has basically contracted Bai Ye's lottery draws over the years. However, Check & Balance Group's reputation is not as good as that of Johnson & Johnson, which limits its market.

Bai Ye felt that the check and balance group needed to go public, and it was entirely possible to make use of the turmoil in the listing of Puxikang to make the check and balance group go public smoothly.

His cooperation with Johnson & Johnson is in the field of medical equipment.

Bai Ye still has a precious opportunity to designate upgrade items. He can use this opportunity to enter the medical inspection market with the help of Johnson & Johnson's platform.

In this market, the country is a short board!
For a long time, Bai Ye didn't want to enter quickly, because medical treatment, such as physiological and biochemical tests, such as some complex large-scale CT machines, nuclear magnetic resonance, etc., definitely not only require the medical field, but also involve many fields such as physics and chemistry. cooperation in the field.

So, it's definitely not as simple as you think.

What Bai Ye wants to take advantage of now is that strengthening opportunity, and hopes to cooperate with Johnson & Johnson Group to go further in the development of medical testing equipment.

In fact, SPOM is the most suitable group in this field, but the only thing that doesn't cooperate is that after dealing with Bai Ye several times, SPOM found that the company's attitude towards China made Bai Ye uncomfortable.

Therefore, Bai Ye found Johnson & Johnson.

If we can keep Johnson & Johnson's core technology in China and benefit China, the contribution will be great.

The person who met with Johnson & Johnson this time was not the Johnson & Johnson company in China, but Mr. Heath, the chief engineer of the Johnson & Johnson headquarters in the United States.

After Heath saw Bai Ye, he smiled and said, "Professor Bai Ye, you are young and promising."

Bai Ye smiled, shook his head and said, "Compared with Mr. Hiss, there is still a gap. I met today to talk to you about our cooperation."

Heath's eyes lit up: "Are you willing to give Puxi Kang to us? Professor Bai Ye, if that's the case, you will definitely not regret what you did today. I believe that our Johnson & Johnson Group can definitely afford one. Satisfied with the numbers!"

Bai Ye shook his head: "No, no, it's not Puxikang. It's another item."

When Heath heard this, he smiled: "Oh? Hehe, is it about the research progress of your research team on tumor cells in this study? Maybe this news surprises me even more!"

Bai Ye continued to shake his head: "Neither, my cooperation with Johnson & Johnson is neither in tumor research nor in the development of new drugs, because what your company is good at is not in the development of new drugs. To be honest, I don't think that working with your company on research Tumor is a good choice, and Pfizer has gone farther than your company in terms of tumor research and development."

"Moreover, to be honest with Mr. Heath, I have already communicated with the management of Pfizer. I hope to conduct in-depth research and cooperation with Pfizer. We are willing to work together in the research and development of tumors."

When Heath heard this, his expression changed drastically!

This is not good news!

Pfizer and Johnson & Johnson have always been competitors. Although there is no exact match for a certain product, there have always been small frictions.

Even in order to prevent the other party from becoming the industry leader, they often stumbling the other party.

in case……

Heath no longer dared to think about it. When he thought of this possibility, he felt a little... scared?
(End of this chapter)